| Registration date | 2022.4.25 |
|---|---|
| Patentee | Quantdetect, Inc. |
| Inventor | Nishizuka, Satoshi / Ishida, Kaoru |
| Out-licensed | Quantdetect, Inc. |
| Summary | A method for producing mouse gastric cancer model using 5-FU resistant gastric cancer cell line, MKN45/5FU. By injecting the MKN45/5FU cell line into submucosal layer of the stomach by liquid separation principle. A xenograft model for the same organ as well as the same layer of the tissue. Useful for validation in cancer metastasis and drug delivery studies. |
|---|
| Registration date | 2019.12.20 |
|---|---|
| Patentee | Iwate Medical University |
| Inventor | Kohei, Kume / Nishizuka, Satoshi |
| Summary | A toxin called α-Amanitin from the “death cap” (Amanita phalloides) suppresses peritonitis carcinomatosa, the status of cancer cell dissemination into the abdominal cavity. The toxin is lethal when ingested but the toxicity is minimized when co-administered with cisplatin, an anticancer agent. |
|---|
| Registration date | 2019.11.29 |
|---|---|
| Patentee | Iwate Medical University |
| Inventor | Kume, Kohei / Nishizuka, Satoshi |
| Summary | The invention relates to a method for molecular profiling of small number of cell subpopulations of cancer cells that survive under presence of anticancer drugs. |
|---|
| Registration date | 2019.11.1 |
|---|---|
| Patentee | Iwate Medical University |
| Inventor | Kume, Kohei / Nishizuka, Satoshi |
| Summary | A advanced cancer disease status, namely peritonitis carcinomatosa, is often resistant to various treatments. The invention relates to TAF15 gene and its product as a therapeutic target. |
|---|
| Registration date | 2019.6.28 |
|---|---|
| Patentee | Quantdetect, Inc. |
| Inventor | Nishizuka, Satoshi / Iwaya, Takeshi |
| Out-licensed | Quantdetect, Inc |
| Summary | A set of targeted nucleic acid reagents for highly sensitive detection of circulating tumor DNA as a tumor marker. The invention relates to variety of diagnosis including post-treatment earlier relapse prediction, quantitative therapeutic efficacy evaluation, and confirmation of non-relapse status. |
|---|
| Registration date | 2013.6.28 |
|---|---|
| Patentee | Iwate Medical University |
| Inventor | Kume, Kohei / Nishizuka, Satoshi |
| Summary | Quantitative monitoring of cellular network protein level in response to anticancer drugs requires a sufficient number of time-course cell lysates. This invention relates to a large-scale cell lysate collection from >1,000 time-point cell lysates. |
|---|